National Comprehensive Cancer Network



About NCCN

NCCN Guidelines and Compendium Updated

Flash Update Sent March 7, 2012
NCCN has published updates to the NCCN Drugs & Biologics Compendium (NCCN Compendium®) to reflect updates to the 2012 version of the corresponding NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®):

  • Breast Cancer V.1.2012
    • Breast Cancer, Noninvasive
    • Breast Cancer, Invasive
    • Paget's Disease
    • Breast Cancer During Pregnancy

Flash Update Sent March 14, 2012

NCCN has published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia. These NCCN Guidelines® are currently available as Version 1.2012.

  • These new NCCN Guidelines for ALL provide recommendations on the diagnostic evaluation and workup for ALL, and treatment algorithms for AYA and adult patients with Philadelphia chromosome (Ph)-positive and Ph–negative ALL.
  • The Guidelines also include recommendations on the evaluation and management of CNS involvement, response criteria, assessment of minimal residual disease (MRD), and key supportive care measures for patients with ALL.
  • Given the complexity of ALL treatment regimens and the required supportive care measures, it is strongly recommended that patients be treated at a specialized cancer center with expertise in the management of ALL.

The NCCN Guidelines for Acute Lymphoblastic Leukemia can be found on NCCN.org .

NCCN has published updates to the NCCN Guidelines and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Non-Melanoma Skin Cancers. These NCCN Guidelines are currently available as Version 2.2012.

  • Basal Cell Skin Cancer:
    • Based on supporting data and recent FDA approval, vismodegib was added in a footnote as a systemic therapy option to consider for high risk basal cell skin cancer patients with residual disease in whom surgery and radiation are contraindicated and for patients with regional or distant metastases. The footnote reads "Consider clinical trials (preferred) or vismodegib. Combination chemotherapy with cisplatin- or carboplatin-based doublets has produced responses."
    • The Discussion was updated to correspond with the changes in the algorithm.

NCCN has published updates to the NCCN Guidelines for Distress Management. These NCCN Guidelines are currently available as Version 2.2012.

  • A new algorithm was developed that provides recommendations for managing distress in cancer patients with schizophrenia/psychotic disorder.

 

For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.

 

 

 

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved